title: Angioscopic Comparison of Resolute and Endeavor Zotarolimus-Eluting Stents.
abstract: BACKGROUND
  Drug-eluting stents (DES) have reduced late loss and target lesion revascularization through the inhibition of neointimal hyperplasia, but instead increased the risk of very late stent failure due to incomplete neointimal coverage and neoatherosclerosis. Although newer DES are more effective and safer than the first-generation DES, the difference in the condition of the stented lesions between Resolute zotarolimus-eluting stents (R-ZES) and Endeavor zotarolimus-eluting stents (E-ZES) on angioscopy has not been reported.
  
  
  RESULTS
  Consecutive patients who received R-ZES (n=46) or E-ZES (n=46) for de novo lesion of native coronary artery and had 1-year follow-up angioscopy were examined. Yellow color (grade 0-3), neointimal coverage (grade 0-2), heterogeneity score (maximum-minimum neointimal coverage grade) and thrombus (presence or absence) at stented lesion were evaluated. The maximum yellow color grade (1.2±0.9 vs. 0.7±1.0, P=0.005) was higher in R-ZES than in E-ZES. The maximum (1.9±0.3 vs. 1.5±0.5, P<0.001) and minimum (1.1±0.7 vs. 0.4±0.5, P<0.001) coverage grade was higher in E-ZES than in R-ZES. The heterogeneity score was higher in R-ZES than in E-ZES (1.0±0.5 vs. 0.7±0.7, P=0.007). Prevalence of thrombus was not different between the 2 stents (6.5% vs. 2.2%, P=0.4).
  
  
  CONCLUSIONS
  E-ZES had better neointimal coverage with less yellow plaque and lower heterogeneity score than R-ZES. The lesions with E-ZES appeared more stable than those with R-ZES. (Circ J 2016; 80: 650-656).
authors.affiliation: Cardiovascular Division, Osaka Police Hospital.
authors.forename: Yuji
authors.initials: Y
authors.lastname: Nishimoto
authors.forename: Koshi
authors.initials: K
authors.lastname: Matsuo
authors.forename: Yasunori
authors.initials: Y
authors.lastname: Ueda
authors.forename: Ryuta
authors.initials: R
authors.lastname: Sugihara
authors.forename: Akio
authors.initials: A
authors.lastname: Hirata
authors.forename: Ayaka
authors.initials: A
authors.lastname: Murakami
authors.forename: Kazunori
authors.initials: K
authors.lastname: Kashiwase
authors.forename: Yoshiharu
authors.initials: Y
authors.lastname: Higuchi
authors.forename: Yoshio
authors.initials: Y
authors.lastname: Yasumura
mesh_terms: D000368:Aged; D017546:Angioscopy; D050197:Atherosclerosis / Q000209:etiology / Q000473:pathology; D054855:Drug-Eluting Stents; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D058426:Neointima / Q000209:etiology / Q000473:pathology; D058226:Plaque, Atherosclerotic / Q000209:etiology / Q000473:pathology; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives*
chemical_list: C489443:zotarolimus; D020123:Sirolimus